A phase II trial of melphalan or thioguanine in the treatment of patients with advanced renal cell cancer

Urologic Oncology

Volumn 2, Issue 3, 1996, Pages 96-98

  Witte, Robert S ^a   Elson, Paul ^b   Stewart, James A ^c   Malliard, James A ^d   Oken, Martin M ^e   Loehrer, Patrick J ^f  

^a GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d Department of Preventative Medicine   (United States)

^e Virginia Piper Cancer Institute   (United States)

^f INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

chemotherapy; melphalan; Renal cell cancer; thioguanine

Indexed keywords

MELPHALAN; TIOGUANINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; NEPHROTOXICITY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 0030135479     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(96)00073-7     Document Type: Article

References (20)

1. 1. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993;43:7-21.
2. 2. Harris DT. Hormonal therapy and chemotherapy of renal cell carcinoma. Semin Oncol 1983;10(4):422-30.
3. 3. Hahn RG, Temkin NR, Sanlov RD, Perils C, et al. Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. Cancer Treat Rep 1978;62:1093-5.
4. 4. Hahn RG, Bauer M, Wolter J, Creech R, Bennett JM, Wampler G. Phase II study of single agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer. Cancer Treat Rep 1979;63:513-5.
5. 5. Hahn RG, Begg CB, Davis TE. Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer. Cancer Treat Rep 1981;65:711-3.
6. 6. Earhart RH, Elson PJ, Rosenthal SN, Hahn RG, Slayton RE. Phase II study of PALA and AMSA in advanced renal cell carcinoma. Am J Clin Oncol 1983;6:555-60.
7. 7. Elson PJ, Earhart RH, Kvols LK, et al. Phase II studies of PCNU and bisantrene in advanced renal cell carcinoma. Cancer Treat Rep 1987;71:331-2.
8. 8. Elson PJ, Kvols LK, Vogl SE, et al. Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivisin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. Invest New Drugs 1988;6:97-103.
9. 9. Creagan ET, Twito DI, Johansson SL, et al. A randomized prospective assessment of recombinant leukocyte A interferon with and without aspirin in advanced renal cell adenocarcinoma. J Clin Oncol 1991;9:2104-9.
10. 10. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alfa interferon in renal cell carcinoma: A randomized trial of two routes of administration. J Clin Oncol 1987;5:286-91.
11. 11. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE, Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993;11:1368-75.
12. 12. Atkins MB, Sparano J, Fisher RI, et al. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993;11:661-70.
13. 13. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, Dekernion J. Concomitant administration of recombinant interleukin-2 and recombinant interferon alfa-2A: An active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992;10:414-21.
14. 14. Alberts DS, Chang SY, Chen HS, et al. Kinetics of intravenous melphalan. Clin Pharmacol Therapy 1979;26:73-80.
15. 15. Alberts DS, Peng YM, Fisher B. Minimal melphalan (L_PAM) systemic availability (SA): Potential cause for failure of adjuvant breast cancer therapy trials. Proc ASCO 1984;3:38.
16. 16. Rohrbaugh TM, Belasco JB, Rosenstock JR, et al. Toxicity of cyclic intravenous melphalan (IVM) in children with refractory malignancies. Proc ASCO 1982;1:12.
17. 17. Kovach JS, Rubin J, Creagan ET, et al. Phase I trial of parenteral 6-thioguanine given over 5 consecutive days. Can Research 1986;46:5959-62.
18. 18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
19. 19. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Research 1988;48:7310-3.
20. 20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.